Clinical and mechanistic responses to a music-based intervention for pain in adults with irritable bowel syndrome: Protocol for a single-arm pilot study
Wu, W., You, E., Li, A., Chen, J., Colloca, L., Kiley, S., Faremi, B., Wong, C. J., et al.
pain medicine
Quick verdict
Protocol-only pilot (N=36, single-arm, 4-week monochord music for IBS pain) with rich multimodal measures; rigorously specified but lacks any control arm.
Summary
This medRxiv preprint is a study protocol, not a results paper. It specifies a single-arm pilot mechanistic trial of a music-based intervention (MBI) for abdominal pain in adults with irritable bowel syndrome. Thirty-six participants aged 18–50 with provider-confirmed IBS and average pain ≥3/10 will be enrolled; about 30 are expected to complete the Week-5 laboratory visit. After a baseline lab visit, participants practice a standardized 20-minute session — 5 minutes guided relaxation, 10 minutes listening to a single monochord recording (~131 Hz fundamental), 5 minutes recovery — at home at least five days per week for four weeks, using a study app plus wearable EEG/fNIRS (Muse S Athena) and ECG/EDA/EMG belt and wrist monitors. Assessments include patient-reported outcomes (primary: BPI pain severity at Week 5 via mixed models, two-sided alpha .05), quantitative sensory testing, 16S rRNA gut microbiome profiling, and feasibility metrics (recruitment, retention, adherence, data completeness, acceptability). The trial is registered (NCT06706778) and transparently framed as hypothesis-generating. Main limitations: no control arm against placebo/expectancy and natural symptom fluctuation; small pilot sample with many exploratory mechanistic outcomes; evaluation of the vendor-developed OIME pain index by authors affiliated with its developer; recruitment had not yet begun.
Review complete
Assessment at a glance
5
risk flags identified
● high 1
● medium 3
● low 1
5 strengths · 5 weaknesses · 5 author questions
AI text signal = Binoculars zero-shot detector score over 20 sampled passages (Fast-DetectGPT co-reported) — absence does not prove human authorship, and a flag does not imply misconduct.
Levels reflect verification complexity — not a quality score. Evolve never rates your paper.
Key claims under review
- A standardized 20-minute monochord MBI (5-min relaxation / 10-min listening / 5-min recovery) can be delivered with measurable fidelity across guided lab sessions and four weeks of app-supported home practice.
- Candidate brain-gut mechanisms (central neural, autonomic/stress, somatic pain sensitivity, exploratory gut microbial) can be captured with multimodal wearables in both laboratory and everyday settings.
- The previously developed OIME machine-learning index can generate objective estimates of IBS pain intensity comparable to concurrent real-time VAS ratings.
- Feasibility metrics (recruitment, retention, MBI and wearable adherence, data completeness, acceptability) will inform the design of a future adequately powered randomized controlled trial.
Strengths
Registered, guideline-aligned protocol
ClinicalTrials.gov NCT06706778 and IRB #2000039033; intervention specified per the NIH Music-Based Intervention Toolkit (Edwards 2023) and Robb 2025 reporting guidelines, with NIH Behavior Change Consortium fidelity framework (Bellg 2004).
Unusually precise stimulus standardization
A single 25-string all-C monochord recording used for every session and participant, with reported acoustic analysis (~131 Hz C3 fundamental in >93% of pitched frames, stable spectra, minimal drift).
Genuinely multimodal brain-gut battery
Feasibility aims are concretely operationalized
Honest scoping of inference
Weaknesses
Single-arm design caps all inference
Vendor COI around the OIME index
Multiplicity versus pilot sample size
Indication-driven dose heterogeneity
Consumer-grade EEG for theta claims
Full Review Report
$1.99 · one-timeUnlock the complete preliminary analysis Evolve produced for this paper.
Report preview
Scope & Claims
This medRxiv preprint (posted 2026-09-17) is a **protocol paper** with no outcome data. It pre-specifies a single-arm pilot mechanistic trial of a music-based intervention (MBI) for IBS-related abdominal pain. Two aims: (1) characterize changes in IBS pain and candidate mechanisms across four domains — central neural processing, autonomic/stress regulation, somatic pain sensitivity, and gut microbial processes (the last explicitly exploratory, Figure 1); (2) test the feasibility of multimodal wearable monitoring (Muse S Athena EEG+fNIRS; Zemi belt ECG/EDA/EMG plus wrist EDA) during four weeks of home practice. The claims are prospective: that a standardized 20-minute monochord protocol (5-min relaxation / 10-min listening / 5-min recovery, ≥5 days/week) is deliverable with measurable adherence; that the brain-gut battery captures mechanistic responses in lab and home; and that the machine-learning OIME index can estimate IBS pain against real-time VAS. Registration (NCT06706778), IRB approval (#2000039033), and pilot-scoped framing keep the claim set appropriately modest.
The remaining sections cover Methodology Assessment, Statistical Evidence, Results & Reproducibility, Limitations & Risks, and Verdict & Recommendations.
- All 5 strengths & 5 weaknesses, analyzed in detail
- 5 risk flags with severity, section & reviewer questions
- Methods & statistical evidence assessment
- 5 questions a peer reviewer would ask
- Full six-dimension evaluation report & recommendations
One-time purchase · this paper only
One-time purchase, this paper only. AI-generated preliminary analysis — not peer review.
Frequently asked questions
Does this paper report results of music therapy for IBS?
No. It is a study protocol for a single-arm pilot trial that had not yet begun recruiting when written. It plans to enroll 36 adults with IBS for a four-week home music-listening program with wearable physiological monitoring; no outcome data exist in this preprint.
What is the music-based intervention in this study?
A standardized 20-minute session practiced at least five days per week for four weeks at home (plus guided lab sessions): 5 minutes of relaxation, 10 minutes listening to a single monochord recording tuned entirely to C (fundamental about 131 Hz), and 5 minutes of quiet recovery.
Is the trial registered, and who can participate?
Yes. It is registered at ClinicalTrials.gov (NCT06706778) and approved by the Yale IRB (#2000039033). Eligible participants are adults aged 18-50 with a provider-confirmed IBS diagnosis and average abdominal pain of at least 3/10 over the prior three months.
What are the main limitations of this planned study?
It is single-arm with no control group, so placebo/expectancy effects and natural symptom fluctuations cannot be separated from any observed change; the sample (~30 completers) suits feasibility but not efficacy claims; and many mechanistic measures are exploratory with limited statistical power.
About this review
This is an AI-generated preliminary review by Evolve.Pub, produced from the openly available text of the paper. It is not peer review and does not represent the authors' views. The canonical record of the paper is at the publisher link above.
- Figures 1-3 (conceptual framework, session structure, study flow) appear as caption text only; visual content was not analyzable.
- Supplementary Appendix S1 (detailed statistical analysis plan, sample-size supplement) was not part of the extracted text; the statistical review relies on the main-text summary.
- medRxiv preprint, not peer reviewed; as a protocol paper it contains no results, so all judgments concern design, specification, and reporting quality.
- Extracted text contains repeated copyright-banner artifacts; they are non-substantive and did not impede review.
Go deeper on this paper
Wrote a paper? Stress-test it before reviewers do.
Upload your manuscript for the same structured scrutiny — reasoning, statistics, evidence, figures, and reproducibility.